| scholarly article | Q13442814 |
| case report | Q2782326 |
| P6179 | Dimensions Publication ID | 1091834543 |
| P356 | DOI | 10.1186/S40425-017-0278-6 |
| P932 | PMC publication ID | 5604351 |
| P698 | PubMed publication ID | 28923102 |
| P50 | author | Arlene Sharpe | Q27094228 |
| Elizabeth Jaffee | Q29452184 | ||
| Derek A. Wainwright | Q42554949 | ||
| Kwok Kin Wong | Q42687956 | ||
| Andrew Zloza | Q61127982 | ||
| Mark B Headley | Q80233819 | ||
| Amanda W. Lund | Q84020463 | ||
| Karolina Palucka | Q88703198 | ||
| P2093 | author name string | Lisa M Coussens | |
| Mario Sznol | |||
| Marcus W Bosenberg | |||
| Philip J Gotwals | |||
| P2860 | cites work | Prevention of allogeneic fetal rejection by tryptophan catabolism | Q24336018 |
| Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes | Q24630783 | ||
| Vaccines for pancreatic cancer | Q26825850 | ||
| One mouse, one patient paradigm: New avatars of personalized cancer therapy | Q27023342 | ||
| Visualization of immediate immune responses to pioneer metastatic cells in the lung. | Q27314749 | ||
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma | Q34214330 | ||
| Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. | Q34276759 | ||
| Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity | Q34625640 | ||
| Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance | Q35558646 | ||
| Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements | Q35568077 | ||
| Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors | Q35570260 | ||
| Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity | Q35634752 | ||
| The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers | Q35799028 | ||
| Human melanoma metastasis in NSG mice correlates with clinical outcome in patients | Q35849516 | ||
| IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival | Q36405905 | ||
| Receptor editing and genetic variability in human autoreactive B cells. | Q36455313 | ||
| Structures of PD-1 with its ligands: sideways and dancing cheek to cheek | Q36802593 | ||
| Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity | Q36884768 | ||
| IDO activates regulatory T cells and blocks their conversion into Th17-like T cells | Q36914732 | ||
| Humanized mice for immune system investigation: progress, promise and challenges | Q37111994 | ||
| Lymphatic vessels regulate immune microenvironments in human and murine melanoma | Q37217526 | ||
| Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients | Q37398064 | ||
| Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. | Q37402009 | ||
| Humanized Mouse Models of Clinical Disease | Q37614202 | ||
| Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. | Q37970302 | ||
| Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. | Q38110540 | ||
| "In vitro" 3D models of tumor-immune system interaction | Q38211137 | ||
| Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. | Q38665092 | ||
| UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. | Q38708831 | ||
| Coinhibitory Pathways in Immunotherapy for Cancer | Q38755150 | ||
| The role of myeloid cells in cancer therapies | Q38875474 | ||
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 | ||
| The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations | Q39692283 | ||
| Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. | Q40031362 | ||
| Improved Human Erythropoiesis and Platelet Formation in Humanized NSGW41 Mice | Q41457201 | ||
| IDO expressing fibroblasts promote the expansion of antigen specific regulatory T cells | Q42281056 | ||
| Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase | Q44135171 | ||
| VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis. | Q50972973 | ||
| Trial watch: phase II and phase III attrition rates 2011-2012. | Q55057294 | ||
| Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. | Q55463248 | ||
| Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice | Q57253376 | ||
| VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics | Q84621185 | ||
| Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors | Q87117523 | ||
| P433 | issue | 1 | |
| P921 | main subject | immunotherapy | Q1427096 |
| workshop | Q27556165 | ||
| P304 | page(s) | 77 | |
| P577 | publication date | 2017-09-19 | |
| P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
| P1476 | title | Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer | |
| P478 | volume | 5 |
Search more.